Intravenous topiramate: Comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers

Epilepsia

Volumn 54, Issue 6, 2013, Pages 1099-1105

  Clark, Anne M ^a   Kriel, Robert L ^b,c   Leppik, Ilo E ^c,d   Marino, Susan E ^b,c   Mishra, Usha ^b,c   Brundage, Richard C ^c   Cloyd, James C ^b,c  

^a Upsher Smith Laboratories Inc   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d MINCEP Epilepsy Care   (United States)

Author keywords

Antiepileptic drug; Intravenous; Pharmacokinetics; Topiramate

Indexed keywords

BETA CYCLODEXTRIN SULFOBUTYL ETHER; TOPIRAMATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ATAXIA; BIOEQUIVALENCE; BLOOD PRESSURE; BLOOD SAMPLING; COMPARATIVE STUDY; DISTRIBUTION VOLUME; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INTOXICATION; DRUG SAFETY; ECCHYMOSIS; ELECTROCARDIOGRAPHY; FATIGUE; FEMALE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART RATE; HIP PAIN; HUMAN; HUMAN EXPERIMENT; INFANTILE SPASM; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; NORMAL HUMAN; NYSTAGMUS; OPEN STUDY; PILOT STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RASH; TASTE DISORDER; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTICONVULSANTS; BLOOD PRESSURE; FEMALE; FRUCTOSE; HEART RATE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NAUSEA; PARESTHESIA; VOMITING;

EID: 84878576891     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12134     Document Type: Article

References (20)

1. Bittigau P, Sifringer M, Ikonomidou C,. (2003) Antiepileptic drugs and apoptosis in the developing brain. Ann N Y Acad Sci 993: 103-114; discussion 123-124.
2. Cha BH, Silveira DC, Liu X, Hu Y, Holmes GL,. (2002) Effect of topiramate following recurrent and prolonged seizures during early development. Epilepsy Res 51: 217-232.
3. Conway JM, Birnbaum AK, Kriel RL, Cloyd JC,. (2003) Relative bioavailability of topiramate administered rectally. Epilepsy Res 54: 91-96.
4. Doose DR, Streeter AJ,. (2002) Topiramate-chemistry, biotransformation, and pharmacokinetics. In, Levy RH, Mattson RH, Meldrum BS, Perucca E, (Eds) Antiepileptic drugs. 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA, pp. 727-734.
5. Doose DR, Walker SA, Gisclon LG, Nayak RK,. (1996) Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. J Clin Pharmacol 36: 884-891.
6. Easterling DE, Zakszewski T, Moyer MD, Margul BL, Marriott TB, Nayak RK,. (1988) Plasma pharmacokinetics of topiramate, a new anticonvulsant in humans. Epilepsia 29: 662.
7. Filippi L, La Marca G, Fiorini P, Poggi C, Cavallaro G, Malvagia S, Pellegrini-Giampietro DE, Guerrini R,. (2009) Topiramate concentrations in neonates treated with prolonged whole body hypothermia for hypoxic ischemic encephalopathy. Epilepsia 50: 2355-2361.
8. Follett PL, Deng W, Dai W, Talos DM, Massillon LJ, Rosenberg PA, Volpe JJ, Jensen FE,. (2004) Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: a protective role for topiramate. J Neurosci 24: 4412-4420.
9. Glier C, Dzietko M, Bittigau P, Jarosz B, Korobowicz E, Ikonomidou C,. (2004) Therapeutic doses of topiramate are not toxic to the developing rat brain. Exp Neurol 187: 403-409.
10. Koh S, Tibayan FD, Simpson JN, Jensen FE,. (2004) NBQX or topiramate treatment after perinatal hypoxia-induced seizures prevents later increases in seizure-induced neuronal injury. Epilepsia 45: 569-575.
11. Kriel R, Clark A, Leppik I, Marino S, Brundage R, Cloyd J,. (2010) Pharmacokinetics and safety of intravenous topiramate in adult patients. American Epilepsy Society Meeting, San Antonio, Tx Abst. 1.285.
12. Lambrecht JL, Shekh-Ahmad T, Todd WM, Halvorsen MB, Bialer M,. (2011) Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate. Epilepsia 52: 1877-1883.
13. Lee SR, Kim SP, Kim JE,. (2000) Protective effect of topiramate against hippocampal neuronal damage after global ischemia in the gerbils. Neurosci Lett 281: 183-186.
14. May TW, Rambeck B, Jurgens U,. (2002) Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication. Ther Drug Monit 24: 366-374.
15. Niebauer M, Gruenthal M,. (1999) Topiramate reduces neuronal injury after experimental status epilepticus. Brain Res 837: 263-269.
16. Painter MJ, Scher MS, Stein AD, Armatti S, Wang Z, Gardiner JC, Paneth N, Minnigh B, Alvin J,. (1999) Phenobarbital compared with phenytoin for the treatment of neonatal seizures. N Engl J Med 341: 485-489.
17. Sachdeo RC,. (1998) Topiramate. Clinical profile in epilepsy. Clin Pharmacokinet 34: 335-346.
18. Silverstein FS, Ferriero DM,. (2008) Off-label use of antiepileptic drugs for the treatment of neonatal seizures. Pediatr Neurol 39: 77-79.
19. Topamax package insert. (2012) Janssen Pharmaceuticals, Inc. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=21628112-0c47-11df-95b3- 498d55d89593.
20. Yang Y, Shuaib A, Li Q, Siddiqui MM,. (1998) Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization. Brain Res 804: 169-176.